Association of p53 Arg72Pro Polymorphism with Esophageal Cancer: A Meta-Analysis Based on 14 Case-Control Studies

被引:16
作者
Zhao, Lanjun [1 ,2 ]
Zhao, Xilong [3 ]
Wu, Xiaoming [1 ,2 ]
Tang, Wenru [1 ,2 ]
机构
[1] Kunming Univ Sci & Technol, Fac Environm Sci & Engn, Kunming 650500, Peoples R China
[2] Kunming Univ Sci & Technol, Fac Med, Lab Mol Genet Aging & Tumor, Kunming 650500, Peoples R China
[3] Chengdu Mil Command, Kunming Gen Hosp, Dept Pathol, Chengdu, Peoples R China
基金
美国国家科学基金会;
关键词
SQUAMOUS-CELL CARCINOMA; HUMAN LUNG-CANCER; CODON; 72; POLYMORPHISM; GENETIC POLYMORPHISMS; CHINESE POPULATION; RISK-FACTORS; MUTATIONS; SUSCEPTIBILITY; VARIANTS; ETIOLOGY;
D O I
10.1089/gtmb.2013.0103
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: The p53 tumor suppressor gene Arg72Pro polymorphism has been associated with esophageal cancer. However, the results were not consistent. Herein, this meta-analysis was performed to estimate the association between p53 Arg72Pro polymorphism and esophageal cancer. Methods: Electronic search of PubMed was conducted to select studies. Studies containing available genotype frequencies of Arg72Pro were chosen, and pooled odds ratio (OR) with 95% confidence interval (CI) was used to assess the association. Results: The final meta-analysis included 14 published studies with 4184 esophageal cancer cases and 7308 controls. The results suggested that the variant genotype was associated with the esophageal cancer risk in additive model (Pro vs. Arg: OR=1.146, 95% CI: 1.016-1.293, p=0.027) and in recessive model (Pro/Pro vs. Arg/Arg+Arg/Pro: OR=1.258, 95% CI: 1.021-1.551, p=0.031). In the stratified analysis by ethnicity, the data suggested that the increased esophageal cancer risk associated with p53 Arg72Pro polymorphism was more evident in the Asian group. The symmetric funnel plot, the Egger's test (p>0.05) and the Begg's test (p>0.05) suggested the lack of publication bias. Conclusion: This meta-analysis suggests that p53 codon 72 polymorphism contributes to esophageal cancer risk, especially in Asians. To validate this association, further studies with more participants worldwide are needed to examine association between this polymorphism and esophageal cancer.
引用
收藏
页码:721 / 726
页数:6
相关论文
共 52 条
[1]  
Bennett WP, 1999, J PATHOL, V187, P8, DOI 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO
[2]  
2-Y
[3]   iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72 polymorphic p53 [J].
Bergamaschi, Daniele ;
Samuels, Yardena ;
Sullivan, Alexandra ;
Zvelebil, Marketa ;
Breyssens, Hilde ;
Bisso, Andrea ;
Del Sal, Giannino ;
Syed, Nelofer ;
Smith, Paul ;
Gasco, Milena ;
Crook, Tim ;
Lu, Xin .
NATURE GENETICS, 2006, 38 (10) :1133-1141
[4]  
Brady CA, 2010, J CELL SCI, V123, P2527
[5]   When mutants gain new powers: news from the mutant p53 field [J].
Brosh, Ran ;
Rotter, Varda .
NATURE REVIEWS CANCER, 2009, 9 (10) :701-713
[6]  
Cai L, 2006, CANCER EPIDEM BIOMAR, V15, P294
[7]   Genetic Associations of 115 Polymorphisms with Cancers of the Upper Aerodigestive Tract across 10 European Countries: The ARCAGE Project [J].
Canova, Cristina ;
Hashibe, Mia ;
Simonato, Lorenzo ;
Nelis, Mari ;
Metspalu, Andres ;
Lagiou, Pagona ;
Trichopoulos, Dimitrios ;
Ahrens, Wolfgang ;
Pigeot, Iris ;
Merletti, Franco ;
Richiardi, Lorenzo ;
Talamini, Renato ;
Barzan, Luigi ;
Macfarlane, Gary J. ;
Macfarlane, Tatiana V. ;
Holcatova, Ivana ;
Bencko, Vladimir ;
Benhamou, Simone ;
Bouchardy, Christine ;
Kjaerheim, Kristina ;
Lowry, Ray ;
Agudo, Antonio ;
Castellsague, Xavier ;
Conway, David I. ;
McKinney, Patricia A. ;
Znaor, Ariana ;
McCartan, Bernard E. ;
Healy, Claire M. ;
Marron, Manuela ;
Brennan, Paul .
CANCER RESEARCH, 2009, 69 (07) :2956-2965
[8]  
Cao Yan-Yan, 2007, Ai Zheng, V26, P1052
[9]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[10]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188